Lisa LeCointe-Cephas Named Chief Compliance Officer at Johnson & Johnson Innovative Medicine

🔑 Key Takeaways

• Lisa LeCointe-Cephas appointed as Chief Compliance Officer for Johnson & Johnson Innovative Medicine.
• She brings over 15 years of experience in compliance, litigation, and regulatory law in life sciences.
• Previously held senior roles at a global biopharmaceutical firm and served as partner at DLA Piper.
• Holds degrees from Yale University (B.A. in Psychology) and Columbia Law School (J.D.).
• Her new role will focus on compliance strategy, crisis management, and industry-specific legal challenges.

📰 Full Story

Johnson & Johnson has officially announced the appointment of Lisa LeCointe-Cephas as the Chief Compliance Officer for its Innovative Medicine division. This strategic hire underscores the company’s continued investment in strengthening ethical standards and global compliance within its pharmaceutical and medical device operations.

LeCointe-Cephas brings more than 15 years of leadership in the life sciences and legal fields. She previously held the role of Senior Vice President – Global Chief Ethics and Compliance Officer at a top biopharmaceutical firm, where she oversaw compliance programs spanning multiple geographies and functions. She was instrumental in shaping policies that aligned with international laws, industry regulations, and internal codes of conduct.

Before her in-house leadership experience, LeCointe-Cephas served as Partner and Chair of the Life Sciences Sector at DLA Piper, a global law firm. There, she specialized in guiding pharmaceutical and medical device companies through complex litigation, regulatory enforcement, and crisis management.

Her appointment at Johnson & Johnson is expected to further reinforce the company’s compliance infrastructure, especially as the pharmaceutical industry continues to navigate evolving global regulatory landscapes.

With degrees from Yale University and Columbia Law School, LeCointe-Cephas combines academic rigor with a practical, real-world approach that’s proven effective in high-stakes environments.

She will report directly to J&J’s executive leadership and play a central role in shaping the compliance and risk management strategy across the company’s innovative medicine portfolio.